Amarin Corp Plc (AMRN)

[Whalatane]

Retire. assuming we win the patent appeal .. and in my non professional opinion Singer puts forth a very convincing argument ...there is new clinical data to drive sales of Vascepa ...whenever Amarin wish to more actively promote .
Specifically the lower rate of revasculareization ...study recently published ....and then hopefully "robust " findings from the final results of the EVAPORATE trial ....due later this year . ( correct if wrong please )

The impacts of COVID ( fewer MD office visits etc ) is IMHO probably eating up more of the patent life valuation than this legal challenge .

Kiwi